Protocols · Immune
VIP as aviptadil has been through registered human trials in pulmonary hypertension, sarcoidosis and acute respiratory failure, so its figures are properly documented. Its two-minute half-life explains why almost every protocol is an infusion.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Escalation across consecutive days is the published structure.
Inhalation targets the pulmonary vasculature directly and avoids systemic hypotension.
Bronchoalveolar lavage cytokines were the measured endpoint.
The same arithmetic for every vial size VIP is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
VIP · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit |
|---|---|---|
| 10 mg | 3.33 mg/ml | 33 mcg |
No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Trial figures are in picomoles per kilogram per hour — molar, not mass. VIP is roughly 3326 g/mol, so conversion is essential before comparing to any mg-labelled vial.
Open the reconstitution calculatorThese are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
Youssef MK, Lee RA, Fernandez JP, et al. · Crit Care Med · 2022 · PMID 36044317
Critically ill COVID-19 patients received continuous intravenous infusion of aviptadil (synthetic VIP) at escalating doses over 3 days to assess respiratory failure outcomes.
View the recordBrown SM, Barkauskas CE, Grund B, et al. · Lancet Respir Med · 2023 · PMID 37348524
Patients with COVID-19 hypoxemic respiratory failure received intravenous aviptadil dosed and titrated over a multi-day infusion protocol combined with remdesivir versus placebo.
View the recordPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.
